Clinical trials: PASC Post Acute Sequelae of COVID-19
PASC Post Acute Sequelae of COVID-19
Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection
Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have symptoms that last long after the active infection ends.
- Trial name
- NCT06577467
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Long COVID, Long Covid19
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Trial name
- NCT05965739
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Post-Acute COVID-19, Post-Acute COVID-19 Syndrome
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial
About 10-20% of persons who contract SARS CoV-2 will experience persistent post-acute sequelae of SARSCoV-2 infection (referred here as PASC).
- Conditions
- Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, Long COVID
- Trial name
- NCT06156202
- Testing
- Comprehensive Rehabilitation, Augmented Usual Care
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Pennsylvania
Long COVID, Dysautonomia
Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia
The current pilot study will recruit participants experiencing new, returning, or ongoing symptoms related to COVID-19 illness for at least four weeks after being first infected with SARS-CoV-2.
- Trial name
- NCT05566379
- Testing
- Mindfulness - Mindful Awareness Practices ( MAPs)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Los Angeles
Long COVID, Long Coronavirus Disease 2019 (Covid19)
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Conditions
- Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
- Trial name
- NCT06305793
- Testing
- IVIG (intravenous immunoglobulin), Coordinated Care, Usual Care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Kanecia Obie Zimmerman
Long COVID, Long COVID-19
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple…
- Conditions
- Long COVID, Long COVID-19, Sleep Disturbance
- Trial name
- NCT06404112
- Testing
- Melatonin, Tailored lighting (TL) Active
- Where
- United States
- Volunteers
- 469 people
- Sponsor
- Duke University
Tachycardia, Dyspnea
Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
Most patients with acute COVID-19 (Coronavirus 19) recover within weeks, however a significant number of individuals will develop the post-acute COVID 19 syndrome (PASC).
- Conditions
- Tachycardia, Dyspnea, COVID-19
- Trial name
- PEACE (NCT05096884)
- Testing
- Metoprolol Succinate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Hackensack Meridian Health
COVID-19, SARS CoV-2 Infection
COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients
Long COVID is defined by the persistence or emergence of symptoms for more than 4 weeks beyond the acute phase of Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) infection.
- Trial name
- SURVIVOR (NCT05587868)
- Testing
- COVID-19 Vaccine
- Where
- Indonesia
- Volunteers
- 250 people
- Sponsor
- Universitas Indonesia
Long COVID, Long COVID-19
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple…
- Conditions
- Long COVID, Long COVID-19, Hypersomnia
- Trial name
- NCT06404099
- Testing
- Modafinil, Solriamfetol
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Duke University
LONG-COVID, Post-acute Sequelae of COVID-19
Skeletal Muscle in PASC and ME/CFS Patients
Rationale: A common feature in patients with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are skeletal muscle-related symptoms, such as muscle pain, weakness…
- Conditions
- LONG-COVID, Post-acute Sequelae of COVID-19, ME/CFS
- Trial name
- NCT05225688
- Testing
- Bike exertion test
- Where
- Netherlands
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Post-COVID-19 Syndrome
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC.
- Trial name
- NCT05497089
- Testing
- Temelimab 54mg/kg
- Where
- 14 sites in Italy, Spain and 1 more
- Volunteers
- 203 people
- Sponsor
- GeNeuro SA
COVID-19
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of…
- Trial name
- NCT05946551
- Testing
- Cetirizine, Famotidine
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Neuro-PASC, Long COVID
Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans
Mental health symptoms, including cognitive impairment ("brain fog"), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and…
- Trial name
- PASC (NCT06932237)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- VA Office of Research and Development
Post-acute Sequelae SARS-CoV-2 Infection (PASC)
TDCS-potentiated Generalization of Cognitive Training in the Rehabilitation of Long COVID Symptoms
The overarching goals of this study are to employ cognitive testing to understand how transcranial direct current stimulation (tDCS), when used concurrently with cognitive training tasks, can affect cognitive impairment symptoms…
- Trial name
- NCT05589272
- Testing
- Active tDCS
- Where
- United States
- Sponsor
- University of Minnesota
Post-acute COVID-19 Syndrome
Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers
Participants are being asked to take part in this research study because they have had a previous diagnosis (at least 3 months ago) of COVID-19 and are experiencing persistent, recurrent or even new symptoms, i.e.
- Trial name
- NCT05356936
- Testing
- Vitamin K2 (MK-7), Vitamin D3
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- University Hospitals Cleveland Medical Center
Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)
The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current…
- Trial name
- NCT05092516
- Testing
- Active tDCS
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Massachusetts General Hospital
ME/CFS, Long COVID
LIFT: Life Improvement Trial
The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus…
- Conditions
- ME/CFS, Long COVID, PASC
- Trial name
- LIFT (NCT06366724)
- Testing
- Pyridostigmine, Low-Dose Naltrexone
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Brigham and Women's Hospital
Anosmia, Asymptomatic COVID-19
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19).
- Conditions
- Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza
- Trial name
- NCT05040659
- Testing
- AROMHA Longitudinal Smell Test
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
COVID-19, Post Acute Sequelae of SARS-CoV-2
Mindfulness Intervention for Post-Covid Symptoms
The purpose of this study is to assess the feasibility of using a wearable brain-sensing wellness device (Muse-S) to potentially reduce stress and anxiety during Post-Covid, which is characterized by increased stress and anxiety.
- Trial name
- NCT05199233
- Testing
- Muse S™ Headband system
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving muscle function (metabolism) following moderate exercise in subjects with fatigue-Predominant Post-Acute…
- Trial name
- NCT05152849
- Testing
- AXA1125
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Axcella Health, Inc